... Khokra et al., [129] Liu et al., [130] Gandhi et al., [131] Mene and Kale, [132] Bhoi et al., [133] Henary et al., [134] Malik et al., [135] Mathur, [136] Gupta and Rawat, [137] Shaista and Amrita, [138] Dadmal et al., [139] Gao et al., [140] Prajapati et al., [141] Kai et al., [142] Achaiah et al., [143] Bhat and Belagali, [111] Midhula et al., [144] Nangare et al., [145] Banerjee et al., [146] Jiang et al., [147] Ning et al., [148] Weekes and Westwell, [149] Li and Wang, [150] Yadav et al., [151] Ulrich, [152] Li et al., [153] Jaiswal et al., [154] Pandey and Pal, [155] Zhu et al., [156] Cheng et al., [157] and Zhilitskaya et al. [158] published reviews focusing on the protocols employed for the synthesis of benzothiazole derivatives. Gill et al., [159] Chandrasekhar, [160] Sulthana and Pandian, [161] Gulati et al., [162] Nivatya et al., [163] Henary et al., [164] Gandhi et al., [165] Sharma et al., [166] Ingle and Marathe, [167] Ahmed et al., [168] Patel et al., [169] Seth et al., [170] and Chanchal et al. [171] published review articles highlighting the diverse biological profiles along with the synthetic protocols engaged in the synthesis of benzothiazole derivatives. Bradshaw and Westwell [172] described the development of Phortress, a prodrug with benzothiazole moiety as an anticancer therapeutic agent in the clinic. ...